Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Receivables (2020 - 2023)

Immuneering's Change in Receivables history spans 4 years, with the latest figure at -$1046.0 for Q2 2023.

  • On a quarterly basis, Change in Receivables rose 98.97% to -$1046.0 in Q2 2023 year-over-year; TTM through Mar 2024 was -$1046.0, a 99.62% increase, with the full-year FY2023 number at -$12417.0, up 94.69% from a year prior.
  • Change in Receivables came in at -$1046.0 for Q2 2023, up from -$11371.0 in the prior quarter.
  • The five-year high for Change in Receivables was $278185.0 in Q3 2020, with the low at -$250978.0 in Q4 2021.
  • Historically, Change in Receivables has averaged -$27133.6 across 4 years, with a median of -$17550.5 in 2021.
  • Peak annual rise in Change in Receivables hit 535.73% in 2022, while the deepest fall reached 3847.7% in 2022.
  • Year by year, Change in Receivables stood at -$78035.0 in 2020, then crashed by 221.62% to -$250978.0 in 2021, then surged by 76.98% to -$57763.0 in 2022, then soared by 98.19% to -$1046.0 in 2023.
  • Business Quant data shows Change in Receivables for IMRX at -$1046.0 in Q2 2023, -$11371.0 in Q1 2023, and -$57763.0 in Q4 2022.